Reata, A Wholly Owned Subsidiary Of Biogen

This study tested an experimental drug called RTA 901 in 209 people with diabetic peripheral neuropathic pain (nerve pain from diabetes). The goal was to see if it could safely reduce pain compared to a placebo. The trial was terminated early, so final results are limited.